Aclaris Therapeutics, Pediatrix Therapeutics Ink License Deal For ATI-1777 In Greater China
(RTTNews) - Biopharmaceutical company Aclaris Therapeutics, Inc. (ACRS) and Chinese therapeutic company Pediatrix Therapeutics, Inc. announced that the companies have entered into a license agreement.
Under the license agreement, Aclaris has granted Pediatrix the exclusive rights to develop, manufacture and commercialize ATI-1777, Aclaris' investigational "soft" Janus kinase (JAK) 1/3 inhibitor, for any disease, including atopic dermatitis, in Greater China (Mainland China, Hong Kong, Macau and Taiwan).
Aclaris will retain the rights to develop, manufacture and commercialize ATI-1777 in the rest of the world.
Under the terms of the agreement, Aclaris will receive an upfront payment of $5 million. In addition, Aclaris is eligible to receive milestone payments of up to $91 million if certain development, regulatory and commercial objectives are achieved.
Aclaris is also eligible to receive a tiered royalty ranging from a low-to-high single digit percentage of net sales of ATI-1777 by Pediatrix in Greater China.
For More Such Health News, visit rttnews.com
Aclaris Therapeutics Says Will Discontinue Further Development Of ATI-450 Program
Slightly Weak Start Seen For U.S. Stocks; PCE Data In Focus
Lower Futures Pointing To Weak Start On Bay Street; Canadian GDP, US PCE Data In Focus
Pound Slides Against Majors
FTSE 100 Weak Again, Looks Headed For Weekly Loss
Pound Falls Against Majors
French Stocks Mostly Subdued In Cautious Trade
